MENU
IBRN
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
IBRN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for IBRN with price predictions
Oct 22, 2026

IBRN's Stochastic Oscillator soaring into overbought zone

The Stochastic Oscillator for IBRN moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for IBRN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBRN's RSI Oscillator exited the oversold zone, 14 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on IBRN as a result. In 62 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for IBRN just turned positive on October 20, 2026. Looking at past instances where IBRN's MACD turned positive, the stock continued to rise in 28 of 41 cases over the following month. The odds of a continued upward trend are 68%.

Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in 175 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

IBRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF (IBRN) ETF is 4.08B. The market cap for tickers in the group ranges from 66.62M to 54.79B. ARGX holds the highest valuation in this group at 54.79B. The lowest valued company is CGTX at 66.62M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was 3%. For the same ETF, the average monthly price growth was -11%, and the average quarterly price growth was -8%. BHVN experienced the highest price growth at 29%, while TNXP experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was 47%. For the same stocks of the ETF, the average monthly volume growth was 50% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 39
Price Growth Rating: 67
SMR Rating: 90
Profit Risk Rating: 86
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com
IBRN's Stochastic Oscillator soaring into overbought zone